SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Call TG,Phyliky RL,Noel P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994; 69: 323328.
  • 2
    Zent CS,Ding W,Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Br J Haematol. 2008; 141: 615621.
  • 3
    Dighiero G,Binet J-L. When and how to treat chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 17991801.
  • 4
    Dohner H,Stilgenbauer S,Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 19101916.
  • 5
    Damle RN,Wasil T,Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94: 18401847.
  • 6
    Hamblin T,Davis Z,Gardiner A,Oscier D,Stevenson F. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94: 18481854.
  • 7
    Crespo M,Bosch F,Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 17641775.
  • 8
    Hamblin TJ,Orchard JA,Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002; 99: 10231029.
  • 9
    Rai KR,Sawitsky A,Cronkite EP,Chanana AD,Levy RN,Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219234.
  • 10
    [No authors listed] Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst. 1999; 91: 861868.
  • 11
    Cheson BD,Bennett JM,Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 49904997.
  • 12
    Messmer BT,Messmer D,Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005; 115: 755764.
  • 13
    Shanafelt TD,Witzig TE,Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006; 24: 46344641.
  • 14
    Faderl S,Thomas DA,O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003; 101: 34133415.
  • 15
    Rossmann ED,Lundin J,Lenkei R,Mellstedt H,Osterborg A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J. 2001; 2: 300306.
  • 16
    Osterborg A,Fassas AS,Anagnostopoulos A,Dyer MJ,Catovsky D,Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996; 93: 151153.
  • 17
    Hillmen P,Skotnicki AB,Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007; 25: 55535555.
  • 18
    Osterborg A,Dyer MJ,Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of Campath-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997; 15: 15671574.
  • 19
    Keating MJ,Flinn I,Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99: 35543561.
  • 20
    Lozanski G,Heerema NA,Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004; 103: 32783281.
  • 21
    Huhn D,von Schilling C,Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001; 98: 13261331.
  • 22
    Keating MJ,O'Brien S,Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 40794088.
  • 23
    Kay NE,Geyer SM,Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood. 2007; 109: 405411.
  • 24
    Byrd JC,Rai K,Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005; 105: 4953.
  • 25
    O'Brien SM,Kantarjian H,Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. JClin Oncol. 2001; 19: 21652170.
  • 26
    Nowakowski GS,Dewald GW,Hoyer JD, et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol. 2005; 130: 3642.
  • 27
    Dewald GW,Brockman SR,Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003; 121: 287295.
  • 28
    Jelinek DF,Tschumper RC,Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001; 115: 854861.
  • 29
    Rassenti LZ,Huynh L,Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351: 893901.
  • 30
    Rawstron AC,Villamor N,Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21: 956964.